| Yazarlar (9) |
Doç. Dr. Selin ÖZKAN KOTİLOĞLU
Kırşehir Ahi Evran Üniversitesi, Türkiye |
Dilek Akyüzlü
Ankara Üniversitesi, Türkiye |
|
Mukaddes Asena Yıldırım
|
|
Mustafa Danışman
|
|
H. Ceren Bozmaoğlu
|
|
Kenan Can Tok
Ankara Üniversitesi, Türkiye |
|
Mehmet Gümüştaş
Ankara Üniversitesi, Türkiye |
|
İnci İlhan
Ankara Üniversitesi, Türkiye |
|
Halit Sinan Süzen
Ankara Üniversitesi, Türkiye |
| Özet |
| IntroductionAlcohol withdrawal syndrome (AWS) is not a common medical condition in general population however it affects patients with alcohol use disorder (AUD) and causes severe complications when diagnosed late or left untreated. Diazepam is a benzodiazepine, which is used to treat various diseases such as insomnia, anxiety, muscle spasm, pain and AWS. Compared to other benzodiazepines, diazepam is more efficient to prevent delirium and decrease withdrawal due to its long half-life. Diazepam is metabolised to its main metabolite nordiazepam with the enzymes expressed by CYP2C19 and CYP3A4 genes. It has been reported that metabolic activity of the enzymes encoded by CYP2C19 gene may be varied due to genetic polymorphisms leading a change in the efficiency of treatment via effecting the plasma level of drugs metabolised by CYP2C19.ObjectivesThe aim of this study is to investigate … |
| Anahtar Kelimeler |
| Bildiri Türü | Tebliğ/Bildiri |
| Bildiri Alt Türü | Özet Metin Olarak Yayınlanan Tebliğ (Uluslararası Kongre/Sempozyum) |
| Bildiri Niteliği | Alanında Hakemli Uluslararası Kongre/Sempozyum |
| Bildiri Dili | İngilizce |
| Kongre Adı | 33rdEUROPEAN CONGRESS OF PSYCHIATRY |
| Kongre Tarihi | 05-04-2025 / 08-04-2025 |
| Basıldığı Ülke | İspanya |
| Basıldığı Şehir | Madrid |
| Atıf Sayıları |
